Abstract
Sepsis remains a significant medical problem. TNFα is a central cytokine in sepsis pathophysiology. We conducted a phase IIa trial in patients with severe sepsis to assess the safety and tolerability of an intravenously infused ovine-derived polyclonal anti-TNFα Fab fragment (AZD9773).
Document Type
Presentation
Publication Date
3-11-2011
Digital Object Identifier (DOI)
http://dx.doi.org/10.1186/cc9683
Repository Citation
Morris, Peter E.; Zeno, Brian; Bernard, Andrew C.; Huang, Xiangning; Simonson, Steven G.; and Bernard, Gordon R., "Safety and tolerability of an ovine-derived polyclonal anti-TNFα Fab fragment (AZD9773) in patients with severe sepsis" (2011). Surgery Presentations. 1.
https://uknowledge.uky.edu/surgery_present/1
Notes/Citation Information
Published in Critical Care, v. 15 (Suppl. 1): P263.
© 2011 Morris et al.
From the 31st International Symposium on Intensive Care and Emergency Medicine (Brussels, Belgium: 22-25 March 2011).